Trojan Horse breaks through blood-brain barrier

Here's a breakthrough with two code phrases that always gets our attention: "blood-brain barrier" and "Trojan Horse." The former is a big headache for researchers looking for a way to delivery medication for brain injuries, and the latter is a sneaky solution to many drug-delivery problems.

Scientists, writing in ACS' Molecular Pharmaceutics, say they've successfully used a Trojan Horse method to sneak the stroke medication erythropoietin through the blood-brain barrier. It also could help people with traumatic head injuries, Parkinson's disease, and other chronic brain disorders, they said.

William Pardridge and colleagues explain that erythropoietin is a protective protein that has engendered great medical interest for its potential in protecting brain cells cut off from their normal blood supply by a stroke, or brain attack. Tests, however, show that erythropoietin, like other drugs, cannot penetrate the blood-brain-barrier that surrounds and protects the brain. Other proteins, however, can penetrate the barrier, and the scientists decided to test one of them as a Trojan Horse to sneak in erythropoietin.

The researchers found an antibody that can go through the blood-brain barrier and linked it to erythropoietin to make a hybrid protein. Tests showed that the approach worked in laboratory mice, with the hybrid protein successfully penetrating the blood-brain barrier. The advance will allow scientists to begin testing erythropoietin's effects on mice with simulated stroke and other brain disorders.

- see the release
- and the full text of the study

Suggested Articles

Armed with microrobots and magnetic fields, Pursue scientists are looking to the future of targeted drug delivery, starting with the colon.

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.